Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $180.13M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | $6.23M | N/A | N/A | N/A | $471.00K | $112.00K | $96.00K | $77.00K |
| Gross Profit | $173.90M | N/A | N/A | N/A | $-471.00K | $-112.00K | $-96.00K | $-77.00K |
| Gross Margin | 96.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Expenses | $671.77M | $380.50M | $293.57M | $242.48M | $205.85M | $94.86M | $40.36M | $31.81M |
| Operating Income | $-497.88M | $-380.50M | $-293.57M | $-242.48M | $-206.32M | $-94.97M | $-40.46M | $-31.89M |
| Operating Margin | -276.39% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income | $-465.89M | $-373.63M | $-295.35M | $-241.85M | $-202.24M | $-83.95M | $-32.81M | $-31.15M |
| Net Margin | -258.64% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS (Basic) | $-21.90 | $-19.99 | $-17.23 | $-14.63 | $-13.09 | $-4.73 | $-2.22 | $-2.54 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |